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The	management	 of	 high-risk	 prostate	 cancer	 has	 become	 increasingly	 sophisticated	with	














men	 presenting	with	High	 Risk	 Prostate	 Cancer	 (HR-PC)	 is	 rising	 year	 on	 year	 (2).	 Studies	
from	a	number	of	 centres	have	 shown	 that	primary	 radical	 therapy	 can	be	very	effective;	
however	men	with	 HR-PC	 have	 the	 highest	 incidence	 of	 disease	 relapse	 and	 progression.	
Evidence-based	practice	in	HR-PC	has	been	hampered	by	a	lack	of	appropriate	randomised	
controlled	 studies	 except	 in	 the	 field	 of	 external	 beam	 radiotherapy	 (EBRT).	 As	 a	 result,	
current	 clinical	 management	 is	 mainly	 driven	 by	 data	 from	 large	 case	 series	 and	
observational	 studies.	 To	 address	 this,	 the	 National	 Clinical	 Research	 Institute	 (NCRI)	
Prostate	Cancer	Clinical	Studies	Localised	Sub-group	held	a	1-day	multi-disciplinary	meeting	
on	 HR-PC	 on	 the	 17th	 November	 2014	 in	 London,	 UK.	 The	 remit	was	 to	 evaluate	 current	





pathways	 (from	 definition	 to	management)	 of	 patients	with	 HR-PC	 and	 2)	 to	 identify	 key	
areas	that	required	further	research.	 	Prior	to	the	meeting,	topics	for	discussion	were	pre-
selected	 and	 specific	 members	 of	 the	 group	 were	 asked	 to	 review	 the	 current	 state	 of	
evidence	and	research	on	the	respective	topics	allocated	to	them.		The	findings	were	then	
presented	at	the	meeting	to	the	rest	of	group	followed	by	a	moderated	discussion	in	order	
to	reach	a	consensus	view.	 	The	top	priorities	 in	each	domain	are	 listed	here	 in	the	Tables	








































risk	 stratification	 tools	 that	was	 developed	 for	 localised	 prostate	 cancer	was	 the	D’Amico	
classification.	 In	 this	 classification,	 high-risk	 patients	 are	 grouped	 as	 those	 with	 a	 PSA	
>20ng/ml,	Gleason	score	8-10	or	patients	with	clinical	T2c	and	above.	This	classification	 is	









multi-centre,	 retrospective	 study	 of	 1360	 patients	 with	 HR-PC	 treated	 by	 radical	
prostatectomy	 that	 three	 distinct	 groups	 of	 patients	 could	 be	 identified	 with	 differing	
survival	profiles	(3).		Lowest	risk	patients	were	those	who	had	a	single	high	risk	factor	with	a	
10-year	 prostate	 cancer	 survival	 (PCS)	 rate	 of	 88.3%.	 	 The	 intermediate	 prognosis	 group	
were	patients	with	a	PSA	>20ng/ml	and	stage	cT3-4	while	the	poorest	prognosis	sub-group	
had	all	three	high	risk	factors	(PCS	of	79.7%)	(3).			
The	 group	 noted	 that	 current	 risk	 stratification	 systems	 relied	 mainly	 on	 retrospective	
studies	with	outcomes	based	on	high	volume	academic	centres	with	particular	expertise	in	
the	management	of	HR-PC.	 	 In	 the	 study	by	 Joniau	et	al	 for	example,	as	all	patients	were	







Partly	 because	 of	 this	 intergroup	 heterogeneity,	 there	 has	 been	 intensive	 research	 into	
other	ways	to	better	stratify	patients,	not	only	for	HR-PC,	but	across	the	disease	spectrum.	
The	use	of	molecular	predictive	markers	such	as	the	cell	cycle	progression	panel	(CCP)	and	
the	Oncotype	Dx	 test	 have	 all	 entered	 commercial	 use	on	 this	 basis.	 The	 clinical	 role	 and	
cost-effectiveness	of	these	panels	in	current	clinical	management	remains	to	be	elucidated	
particularly	within	the	context	of	sub-optimal	clinical	risk	prediction	models.	
The	 clinical	 utility	 of	 nomograms	 was	 also	 discussed.	 It	 was	 generally	 agreed	 that	
nomograms	might	be	a	useful	way	of	presenting	a	non-biased,	objective	measure	of	risk	to	




In	 summary,	 there	 is	 evidence	 to	 suggest	 that	 prognosis	 differs	 even	 in	 the	 context	 of	
patients	with	 HR-PC.	 	 Future	 studies	 should	 therefore	 concentrate	 on	 better	 defining	 the	
different	 sub-categories	 that	 may	 exist	 within	 a	 HR-PC	 classification.	 Any	 future	 risk	
prediction	 tools	 need	 to	 be	 developed	 based	 on	 contemporary	 UK	 data	 in	 order	 to	 be	
applicable	and	also	include	patients	from	across	the	spectrum	of	treatments.			
Current	treatment	pathways	and	outcomes	
The	 optimal	 treatment	 for	 patients	with	 HR-PC	 is	 currently	 unknown.	 	 Typically,	 high-risk	
patients	 are	 treated	 with	 EBRT	 with	 neo-adjuvant	 and	 adjuvant	 Androgen	 Deprivation	
Therapy	(ADT)	for	2-3	years.	There	is	evidence	of	improved	overall	survival	for	this	combined	
modality	approach	in	patients	with	locally	advanced	disease	from	two	randomised	trials	(4-
5).	 	 In	 the	NCIC	Clinical	 Trials	Group	PR.3/Medical	Research	Council	 PR07/Intergroup	T94-
0110	trial	patients	who	received	EBRT	and	ADT	had	a	74%	survival	at	7	years	compared	to	
66%	in	men	who	received	ADT	(4).		





compared	 to	 low	 risk	 prostate	 cancer.	 Dasu	 et	 al	 reported	 that	 in	 patients	with	 high-risk	
disease	74	Gy	did	not	achieve	adequate	control	of	the	tumour	with	a	total	radiation	dose	of	
>80Gy	 often	 being	 required	 (7).	 Another	 explanation	 for	 the	 poorer	 EBRT	 response	 could	
also	 be	 a	 higher	 tumour	 burden	 within	 the	 prostate	 in	 men	 with	 HR-PC.	 An	 interesting	
question	in	this	regard	is	whether	the	dose	distribution	of	EBRT	could	be	risk-adapted	and	in	
the	 UK,	 studies	 such	 as	 the	 recently	 completed	 DELINEATE	 trial	 could	 help	 answer	 this	
(ISRCTN:	04483921).	In	this	pilot	study	the	aim	was	to	test	the	value	of	increasing	radiation	
dosage	to	MRI-visible	tumours	within	the	prostate.		
Another	 potential	 method	 by	 which	 the	 effectiveness	 of	 EBRT	 could	 be	 improved	 is	 by	
combination	 with	 other	 agents	 that	 are	 designed	 to	 block	 androgen	 receptor	 signalling.		
Current	 trials	 for	 example	 are	 specifically	 looking	 at	 the	 HR-PC	 group	 and	 whether	 the	
combination	of	EBRT	with	agents	such	as	enzalutamide	can	result	in	a	survival	advantage	(8).		






at	 risk	 of	 an	 occult	 relapse	 (9).	With	 the	 lack	 of	 level	 1	 evidence	 to	 support	 pelvic	 nodal	
irradiation	however,	it	is	unknown	whether	further	extending	the	field	to	include	para-aortic	
nodes	would	 result	 in	 any	 advantage	 for	 these	 patients.	 The	 additional	 toxicity	 is	 also	 of	




in	 patients	with	 HR-PC	 can	 improve	 survival	 outcomes	 in	 patients	who	 are	 being	 treated	
with	 concurrent	 ADT.	 There	 is	 an	 increasing	 ability	 to	 do	 this	with	 precision	 using	 image-
guided	and	intensity	modulated	EBRT	approaches	to	avoid	toxicities	to	surrounding	normal	
tissues.	 Secondly,	 the	 molecular	 mechanism	 by	 which	 ADT	 and	 EBRT	 together	 improves	
survival	 outcome	 is	 also	 not	 well	 understood.	 The	 perceived	 notion	 is	 that	 ADT	 may	 be	
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having	 an	 effect	 on	 early	 micro-metastatic	 disease	 and	 hence	 result	 in	 better	 systemic	
control	and	survival	outcome	 in	 this	group	of	patients.	There	 is	however	no	evidence	that	
ADT	 as	 an	 adjunct	 treatment	 for	 radical	 prostatectomy	 confers	 a	 similar	 survival	 benefit	
though	 this	 question	 remains	 controversial	 (11).	 This	 suggests	 that	 there	 might	 be	 a	
mechanism	unique	to	EBRT.		Such	mechanisms	may	include	the	effect	of	ADT	in	permitting	
quiescent	androgen	receptor	negative	prostate	cancer	stem	cells	to	replicate	thus	allowing	
them	 to	 become	 susceptible	 to	 EBRT.	 There	 is	 also	 emerging	 data	 that	 the	 androgen	









PC	 (15).	 A	 number	 of	 retrospective	 observational	 studies	 have	 suggested	 that	 radical	




regarded	 by	 both	 urologists	 and	 oncologists	 as	 an	 important	 part	 of	 a	 multi-modality	
treatment	approach	in	the	management	of	HR-PC	(17-18).	From	the	outset,	these	patients	
are	 counselled	 that	 they	may	 require	 adjuvant	 treatment	with	 EBRT	and	possibly	ADT.	 	 It	
was	noted	however	 that	 there	 is	no	evidence	 to	 suggest	 the	 superiority	of	 this	 treatment	
modality	 over	 primary	 radiotherapy	 and	 this	 concept	 has	 entered	 mainstream	 practice	
without	 a	 strong	 evidence	 base.	 	 Thus,	 the	 group	 acknowledged	 this	 to	 be	 an	 on-going	
future	clinical	research	priority	and	there	was	a	general	feeling	that	the	UK	would	be	ideally	







These	 include	 disease	 aggressiveness,	 life	 expectancy,	 co-morbidity,	 functional	 outcomes	
and	 complications	 of	 treatment	 as	 well	 as	 the	 consequences	 of	 failed	 primary	 therapy.	
Paramount	 is	 also	 the	 patient’s	 own	 choice	 of	 the	 best	 therapy	 for	 themselves	 based	 on	
considerations	of	quality	of	life	as	well	as	length	of	life	(19).		
	
Data	 from	 the	 literature	 in	 which	 the	 number	 of	 high-risk	 factors	 has	 been	 shown	 to	
influence	outcome	from	radical	prostatectomy	have	already	been	discussed.	It	is	however	as	
yet	 unknown	 if	 this	 is	 also	 the	 case	 for	 EBRT.	 Age	 and	 co-morbidity	 also	 have	 a	 major	
influence	 on	 the	 outcome	 of	 therapy.	 Competing	 risk	 analyses	 that	 have	 been	 published	
from	both	natural	history	(non-treatment)	studies	as	well	as	following	therapy	have	clearly	
shown	 that	 the	benefits	 from	 radical	 treatment	are	mainly	 seen	 in	 younger	men	with	 the	
fewest	co-morbidities	(20-21).	However,	this	will	need	regular	review	within	the	context	of	a	
much	 longer-living	 population	 in	 the	 western	 world	 and	 the	 improving	 general	 health	 of	
men.			
	
Functional	 and	 complication	 outcomes	 between	 EBRT	 and	 surgery	 have	 been	 keenly	
debated	over	the	years	and	there	is	a	significant	lack	of	comparable	data	from	studies	that	
have	used	 similar	 outcome	measures	 between	modalities.	 The	Prostate	Cancer	Outcomes	
Study	 has	 shed	 some	 light	 on	 this	 and	 it	 is	 clear	 that	 radical	 surgery	 and	 EBRT	 confer	
significant	detrimental	 effects	 to	urinary	 and	 sexual	 functions	 although	bowel	dysfunction	
seems	 to	be	 remarkably	 similar	between	 the	 two	groups	 (22).	 This	particular	 study	which	
prospectively	 followed	men	over	15	years	also	demonstrated	that	after	 intervention	there	
was	 a	 gradual	 decline	 in	 all	 domains	 over	 a	 period	 of	 time	which	most	 likely	 reflects	 the	
effect	of	age.	Between	 the	2	modalities	most	 studies	have	shown	that	 surgery	appears	 to	
have	 the	 greatest	 detrimental	 effect	 on	 urinary	 and	 sexual	 function.	 Conversely	
observational	work	by	Nam	et	al	from	Canadaian	registry	data	has	suggested	that	treatment	
by	 EBRT	 may	 have	 an	 increased	 risk	 of	 non-urinary	 and	 erectile	 complications	 requiring	
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hospital	 admissions	 including	 rectal	 or	 anal	 procedures,	 open	 surgical	 procedures	 and	
secondary	malignancies	(23).		
	
The	 group	 discussed	whether	 treatment	 selective	markers	 could	 be	 used	 as	 a	method	 of	
helping	 patients	 and	 clinicians	 choose	 the	 best	 first	 radical	 therapy	 option.	 Biomarker	
research	 in	 this	 area	 is	 very	 sparse	 and	 to	 date	 there	 are	 no	 studies	 which	 have	
demonstrated	 that	 any	 one	 biomarker	 can	 help	 stratify	 patients	 (24).	 There	 is	 however	
emerging	evidence	of	this	being	a	possibility.	An	example	is	the	BRCA2	mutation	(about	2%	
of	the	prostate	cancer	population)	whereby	carriers	of	the	mutation	are	known	to	have	poor	
outcomes	 from	 EBRT	 and	 potentially	 may	 do	 better	 from	 surgery	 instead	 (25).	 Another	
possible	 approach	 is	 to	 consider	 the	 toxicities	 from	 different	 treatments.	 In	 this	 context,	
studies	 are	 currently	 exploring	 how	 genomic	 predictors	 (e.g.	 single	 nucleotide	
polymorphisms)	 might	 identify	 men	 who	 are	 most	 susceptible	 to	 radiation	 damage	 to	
normal	tissue	and	hence	be	better	managed	by	non-EBRT	or	reduced	dose	therapy	methods	
(26).	 UK	 trials	 such	 as	 Radiogenomics:	 Assessment	 of	 Polymorphisms	 for	 Predicting	 the	
Effects	 of	 EBRT	 (RAPPER)	 and	 the	 linking	 radiation	 dose	 at	 the	 VOXel	 level	 with	 TOXicity	
(VOXTOX)	 are	 currently	 exploring	 this	 area	 of	 study	 (UKCRN	 Trials:	 1471	 and	 13716	
respectively).		
	
The	group	concluded	that	currently	 there	 is	no	 level	1	evidence	to	suggest	 the	benefits	of	
one	radical	treatment	option	over	another	and	very	 little	research	 in	stratified	approaches	
to	 therapy.	 In	 this	 context	 the	 discussion	 centred	 on	 the	 patients	 own	 choice	 of	 therapy.	
They	 recognise	 that	 a	 patient’s	 choice	 is	 very	 individual	 and	 can	 rely	 on	 their	 own	
experiences,	 the	 influence	 of	 family	 and	 other	 co-existing	 conditions	 (e.g.	 urinary	 tract	
symptoms)	and	also	 to	a	 large	extent	on	who	they	see	 in	 the	clinics	and	what	counselling	
they	 receive.	 	 Most	 attendees	 agreed	 that	 for	 the	 younger	 or	 fitter	 men	 with	 high-risk	












considering	 constructing	 a	 treatment	 choice	 algorithm.	 This	 might	 include	 the	 factors	
discussed	within	this	topic	area	to	help	the	clinician	and	patient	make	the	most	appropriate	
decision	 for	 radical	 treatment	 to	manage	HR-PC.	 All	meeting	 participants	 recognised	 that	
randomised	 controlled	 trials	 in	 this	 area	 are	 going	 to	 be	 very	 difficult	 to	 achieve	 to	 help	
inform	 such	 an	 algorithm.	 One	 alternative	 option	 however	 is	 to	 consider	 collecting	 data	
prospectively	in	registration	studies	and	to	include	standardised	composite	oncological	and	
quality	 of	 life	measures.	 In	 this	 regard	work	 initiated	 by	 the	 International	 Consortium	 on	




















role	 of	 these	 external	 techniques	 as	 well	 as	 high	 dose	 rate	 (HDR)	 brachytherapy	 in	 the	
management	 of	 HR-PC	was	 identified	 as	 a	 key	 research	 priority.	 Coupled	with	 this	 is	 the	
significant	current	research	interest	in	the	optimal	dose	fractionation	regime	and	timing	as	
well	as	how	this	is	best	combined	with	systematic	therapy.	
The	 UK	 has	 been	 an	 international	 lead	 for	 many	 recent	 innovations	 in	 technical	
radiotherapy.	An	example	of	this	is	the	planned	HEXPROP	study	which	will	be	a	multi-armed	
comparison	 of	 EBRT	 dose	 and	 pelvic	 node	 radiation.	 More	 recently,	 the	 radiotherapy	
community	 has	 been	 considering	 the	 role	 of	 EBRT	 in	 men	 with	 node	 positive	 and	 oligo-
metastatic	 disease	 though	 studies	 in	 this	 area	 are	 at	 an	 early	 stage.	 The	 Dutch	 HORRAD	




Other	 studies	 such	 as	 the	 recently	 funded	 CORE	 study	 	 (Conventional	 care	 versus	
radioablation	 for	 extracranial	 metastases)	 are	 exploring	 the	 benefits	 of	 targeted	 EBRT	 to	
metastatic	sites	in	men	who	have	progressed	despite	primary	androgen	deprivation	therapy.	
Radio-sensitisation	 using	 molecular	 targeted	 drugs	 prior	 to	 EBRT	 was	 identified	 as	 a	
potential	 way	 of	 further	 improving	 oncological	 responses.	 Radio-sensitising	 drugs	 which	
target	 apoptotic	 and	DNA	damage	 response	pathways	 are	due	 to	be	assessed	alone	or	 in	
combination	 in	 future	 trials.	 Tumour	 hypoxia	 is	 known	 to	 affect	 EBRT	 effectiveness	 and	
there	 are	 hypoxia	 modification	 studies;	 e.g.	 PROCON:	 A	 trial	 of	 PROstate	 EBRT	 in	
CONjunction	with	 carbogen	 and	nicotinamide	 (ISRCT:	N08912168)	 being	 conducted	 in	 the	
UK	to	determine	if	reversal	of	hypoxia	might	increase	the	efficacy	of	EBRT.	Radiotherapy	has	
also	been	 suggested	 to	 increase	 the	efficacy	of	 immunotherapy	 in	animal	models	 (28).	 To	
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date	 however	 human	 trials	 in	 the	 castrate	 refractory	 metastatic	 setting	 combining	 bone	
directed	radiotherapy	and	immunotherapy	have	not	so	far	shown	clinical	benefit	(29).		
Non-invasive	 imaging	 of	 the	 in	 situ	 prostate	 to	monitor	 treatment	 response	 such	 as	with	
Magnetic	Resonance	(MR)	or	Positron	Emission	Tomography	(PET)	was	also	discussed	with	
particular	 emphasis	 on	 identification	 of	 treatment	 failure	 before	 biochemical	 detected	
relapse.	 In	 this	context	 the	use	of	 imaging	during	 treatment	with	a	view	to	modulating	or	
escalating	doses	would	be	of	particular	interest.	The	role	and	place	of	MR	targeted	biopsies	
and	their	 timing	 in	relation	to	EBRT	to	 identify	suspected	recurrence	remains	unclear.	The	
use	of	such	biopsy	data	may	be	 informative	 in	confirming	recurrence	and	deciding	 further	
treatment	but	is	limited	by	post	treatment	radiation	atypia	that	can	make	the	diagnosis	and	
Gleason	 grading	 of	 recurrent	 tumours	 very	 difficult	 (30).	 The	 group	 also	 discussed	 the	
evidence	 for	 the	 use	 of	 tissue	 biomarkers	 as	 an	 alternative	 to	 guide	 salvage	 treatment	
choices	and	better	predict	 treatment	 response.	Here	 the	 significant	paucity	of	 research	 in	




1.	 What	 is	 the	 best	 radiotherapy	 fractionation	 regimes	 and	 combinations	 with							
optimised	dose	delivery	for	the	treatment	of	HR-PC?	
2.	 Does	 pelvic	 nodal	 and	 prostate	 ERBT	 have	 better	 oncological	 and	 functional	
outcomes	compared	to	prostate-only	ERBT?			









laparoscopic	 prostatectomy	 (RALP)	 has	 now	 become	 the	 most	 common	 operation	 for	
localised	prostate	cancer	in	the	United	States	and	is	becoming	so	in	the	UK	as	well.	It	is	also	
emerging	 as	 an	 option	 in	 the	 management	 of	 locally	 advanced	 and	 localised	 high-risk	
disease.	 This	 change	 in	 practice	 has	 happened	 despite	 the	 ongoing	 uncertainty	 around	
which	 available	 methods;	 open,	 laparoscopic	 or	 RALP	 is	 the	 most	 effective	 and	 cost-
effective.	 Reviews	 of	 large	 observational	 studies	 have	 reported	 that	 RALP	 is	 at	 least	
comparable	 in	 efficacy	 to	 open	 prostatectomy	 with	 the	 majority	 of	 studies	 reporting	
favourable	 functional	 and	 oncological	 outcomes	 (31-33).	 However,	 these	 types	 of	 studies	
are	inherently	flawed	as	they	are	unable	to	control	for	variations	in	patient	factors,	surgical	
experience	 and	 caseloads,	 all	 of	 which	 can	 have	 a	 significant	 impact	 on	 the	 reported	
outcomes.	The	group	discussed	the	challenges	in	carrying	out	a	randomised	controlled	trial	
and	 questioned	 what	 other	 types	 of	 studies	 would	 be	 a	 reasonable	 alternative.	 The	 UK	
LOPERA	trial	(Laparoscopic,	Open	and	Robot-assisted	prostatectomy	as	treatment	for	organ-
confined	 prostate	 cancer	 ISRCTN:	 59410552)	 for	 instance	 comparing	 different	 types	 of	
radical	prostatectomy	failed	to	recruit	sufficient	patients.	Large	multi-centred	collaborations	
with	prospective	and	accurate	databases	were	deemed	a	potential	and	acceptable	way	of	
assessing	 these	 techniques.	 However,	 the	 group	 recognised	 that	 the	 current	 lack	 of	
standardised	 reporting	 between	 centres	 on	 oncological	 and	 functional	 outcomes	 makes	
direct	comparisons	challenging.			
The	 Royal	 College	 of	 Surgeons	 surgical	 trials	 initiative	 set	 up	 five	 surgical	 trial	 units	 (STU)	
across	 England	 to	 substantially	 increase	 surgical	 research	 capacity.	 The	 STUs	 aim	 to	 help	
support	 researchers	 to	 produce	 high-quality	 research	 that	 can	 benefit	 patients	 through	
improved	 clinical	 outcomes,	 better	 standards	 of	 care	 and	 a	 reduction	 in	 the	 regional	
variations	in	care.	The	units	however	have	reported	on-going	problems	with	gaining	funding,	
over-regulation	and	delays	 in	gaining	ethical	approval.	 	These	UK-wide	challenges	must	be	
addressed	in	order	to	ensure	surgical	 innovation	is	 implemented	promptly	and	safely.	 	The	
group	 also	 felt	 that	 any	 future	 surgical	 research	 should	 account	 for	 surgeon/centre	




The	 role	 of	 surgery	 in	 localised	 and	 locally	 advanced	HR-PC	 disease	was	 identified	 as	 key	
priority	areas	for	future	research.		A	higher	proportion	of	men	are	having	surgery	as	part	of	a	
first	step	in	the	multi-modal	management	of	their	disease.	In	some	patients	surgery	is	a	one-
step	 modality	 with	 excellent	 oncological	 prognosis	 however	 most	 men	 will	 need	 a	
multimodal	 approach.	 A	 key	 research	 area	 is	 in	 defining	 clinical	 or	 biological	 markers	 to	
select	 the	most	 appropriate	HR-PC	 candidates	 for	 surgery	with	 the	highest	 likelihood	of	 a	
good	outcome.	In	addition	this	may	also	help	determine	the	appropriate	sequencing,	timing	
and	intensity	of	multimodal	therapies.	Most	recently	surgery	has	also	been	proposed	as	an	
option	 for	 local	 treatment	 in	 men	 with	 olio-metastatic	 disease	 with	 observational	 data	
suggesting	 better	 biochemical	 and	 survival	 outcomes	 compared	 to	 palliative	 treatment	















and	 multimodal	 approach	 to	 therapy.	 This	 included	 the	 optimal	 local	 therapy	 to	 the	
prostate,	 the	best	modality	 to	 treat	 lymph	nodes	and	the	role	and	timing	of	neo-adjuvant	
and	adjuvant	therapy.	ERBT	with	 long-term	ADT	has	 long	been	considered	the	standard	of	
care	 for	 HR-PC	 over	 other	 modalities.	 There	 still	 remains	 major	 controversy	 about	 the	
appropriate	duration	of	ADT.	The	majority	of	patients	now	have	ADT	started	prior	to	ERBT	
but	it	is	unclear	how	long	the	treatment	duration	should	be	and	how	this	would	differ	in	the	




lymph	node	dissection	may	 improve	biochemical	 relapse	 rates	and	 certainly	provide	good	
staging	 information,	 it	has	not	yet	been	consistently	 shown	 to	 improve	 survival	and	 there	
are	 no	 randomised	 trials	 exploring	 this	 issue	 (36-37).	 Furthermore,	 the	 place	 and	 relative	
benefit	 of	 extended	 lymph	 node	 dissections	 within	 the	 context	 of	 contemporary	 post	
surgical	 adjuvant	 therapy	 is	 unknown.	 The	 group	 noted	 that	 in	 this	 context	 there	was	 an	
opportunity	 to	 explore	 complementary	 roles	 for	 different	modalities	 for	 treatment	 of	 the	
prostate	and	lymph	nodes	within	a	trial	setting.	
	
With	 the	emerging	possibility	of	accurate	molecular	 characterisation	of	 tumours	at	biopsy	
the	group	discussed	how	this	could	be	exploited	to	guide	selection	and	use	of	neo-adjuvant	
or	adjuvant	therapy.	There	was	particular	interest	in	the	possibility	of	prospective	trials	that	
might	 randomise	patients	 to	specific	 treatments	based	on	an	 individualised	understanding	
of	 molecular	 perturbations.	 Here	 options	 for	 targeted	 novel	 neo-adjuvant	 and	 adjuvant	
combinations	 alongside	 standard	 radical	 therapies	 should	be	 explored.	 Indeed	 these	have	
already	begun	with	current	studies	on	the	NCRI	CSG	portfolio	incorporating	novel	drugs	and	









men.	 One	 example	 of	 this	 is	 the	 use	 of	 neo-adjuvant	 docetaxel	 chemotherapy	 prior	 to	




as	 endpoints	 in	 trials	making	 studies	 harder	 to	 compare	 and	 draw	 firm	 conclusions.	 	 The	
group	urged	that	future	research	should	try	and	use	standardised	functional	outcomes	and	





1.	 What	 is	 the	appropriate	 timing,	optimal	duration	and	 type	of	 concurrent	androgen	
deprivation	therapy	in	EBRT	treated	HR-PC?		
2.	 What	 is	 the	optimal	management	of	 lymph	nodes	 in	HR-PC?	Do	patients	do	better	
with	surgical	excision	of	lymph	nodes	or	from	irradiation	of	lymph	nodes	+	ADT?	Can	
the	UK	 lead	 a	 randomised	 trial	 of	 lymph-node	 dissection	 versus	 lymph	 node	 EBRT	
following	radical	prostatectomy?		
3.	 How	can	we	exploit	 the	unique	molecular	 characteristics	of	 tumours	 to	help	 guide	




Men	with	HR-PC	have	 the	highest	 risk	of	 disease	 relapse	 after	 primary	 radical	 therapy.	 In	
post-surgical	 patients,	 salvage	 EBRT	with	 or	without	 ADT	 is	 the	mainstay	 of	management	
though	there	 remains	uncertainty	on	 the	optimal	duration,	dosage	and	timing	of	adjuvant	
treatment.	 These	 issues	have	been	partly	 addressed	by	 recent	 randomised	 adjuvant	 trials	
and	will	be	further	informed	by	the	current	UK	RADICALS	study	(Randomised	Controlled	Trial	
of	Radiology	and	Androgen	deprivation	in	combination	after	local	surgery)	(42-45).		




morbidity	 and	 toxicity.	 There	 have	 been	 no	 randomised	 trials	 in	 this	 area	 and	 these	 are	
difficult	 to	 undertake	 as	 demonstrated	 by	 the	 failed	 CROP	 trial	 (deferred	 androgen	
deprivation	 therapy	 +/-	 upfront	 CRyOtherapy	 in	 men	 with	 localised	 radiation	 recurrent	
prostate	 cancer)	 (46).	Nevertheless,	 local	 salvage	 therapy	has	 the	potential	 to	be	 curative	
and	disease	control	has	been	reported	in	a	substantial	number	of	selected	patients.		Further	
research	 is	 required	 to	 determine	which	 patients	 should	 be	 offered	 local	 salvage	 therapy	
and	whether	or	not	the	therapeutic	advantage	is	enough	to	justify	the	associated	treatment-
related	morbidity.		
The	group	agreed	 that	 there	was	no	 level	1	evidence	available	 to	help	guide	clinician	and	
patient	decision	making	and	the	current	literature	is	lacking	on	good	quality	data	regarding	
treatment-associated	morbidity.	 Indeed	 it	 is	 currently	unknown	how	many	men	 in	 the	UK	
with	 radio-recurrent	 disease	 are	 offered	 and	 received	 salvage	 therapy.	 A	 further	
complication	 is	 the	diversity	of	oncological	outcome	measures	used	with	different	 salvage	
modalities.	 The	 timing	 and	 duration	 of	 adjuvant	 ADT	 with	 salvage	 therapy	 is	 also	 a	 key	
question	that	needs	to	be	answered.	The	group	agreed	that	a	UK	prospective	database	for	
all	men	who	received	salvage	therapy	should	be	developed	and	established.	This	may	be	the	
only	 viable	 alternative	 to	 a	 randomised	 controlled	 trial	 though	 the	 group	 recognised	 that	





















The	 group	 recognised	 that	 the	 UK	 was	 well	 placed	 to	 undertake	 balanced	 and	 equitable	
research	 in	 HR-PC	 and	 that	 this	 was	 best	 achieved	 using	 a	 multi-disciplinary	 approach	
involving	 surgeons,	 oncologists,	 pathologists,	 radiologists	 and	 other	 allied	 medical	
specialities.	 Indeed	 the	 UK	 already	 has	 nationally	 endorsed	 standards	 for	 individual	 case	








sub-classifying	men	with	 high-risk	 disease	 to	 identify	 those	who	will	 and	will	 not	 do	well	
from	current	therapies.		At	the	moment,	the	inclusion	of	all	men	with	high-risk	disease	into	a	
	 21	
single	 group	 is	 untenable	 for	 future	 research	 and	 to	 achieve	 improvements	 in	 individual	
clinical	outcomes.		Thus	better	risk	models	need	to	be	defined	and	importantly	use	cohorts	




A	 critical	 issue	 for	 both	 primary	 surgery	 and	 EBRT	 is	 how	 to	 deal	 with	 lymph	 node	
involvement	as	this	area	lacks	good	evidence-based	clinical	guidelines.	New	research	in	this	
field	may	well	need	to	avoid	the	traditional	separations	of	surgery	and	EBRT.	One	consistent	
research	 theme	 was	 whether	 surgery	 or	 EBRT	 (potentially	 including	 ADT)	 was	 the	 better	












Finally,	 it	was	 recognised	 that	going	 forward	 it	 is	 the	 integration	of	molecular	 information	
derived	 at	 the	 beginning,	 during	 and	 after	 treatment	 that	 is	 going	 to	 define	 the	 next	




In	 conclusion	 it	 is	hoped	 that	 the	discussions	and	consensus	 from	this	meeting	 report	will	
help	 the	 UK	 Prostate	 Cancer	 Research	 Community	 to	 focus	 their	 research	 in	 HR-PC	 and	
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